Krystexxa (pegloticase)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Krystexxa (pegloticase), covering 2023-10-10 to 2026-04-09. Get the full timeline:
Most recent: Clinical Trial Update: A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout [Phase 4]